MedTech Strategist Top 5: October 2021

article image
ARTICLE SUMMARY:

The five most-read MedTech Strategist articles posted in October to MyStrategist.com: ShangBay Capital's approach to medtech investing, Glenn Snyder and Paul Grand discuss findings from the recent MedTech Innovator/Deloitte survey on medtech start-up trends, highlights from NASS 2021, and near-term opportunities in the neural interface field.

The top five MedTech Strategist October articles, based on readers’ views. Subscribers, click through to read the full articles. Non-subscribers, take advantage of our free trial offer.

#1: ShangBay Capital’s Focus on Medtech

The medtech -focused venture firm has Chinese roots, but a close-to-home US investment strategy. We speak with founding managing partner William Dai.

#2:The Shifting Start-Up Ecosystem: Insights on the Future of Medtech

Medtech start-ups are shifting away from traditional therapeutic devices toward proactive care solutions, with a heavy emphasis on advanced digital capabilities, according to a recent analysis from Deloitte Consulting and MedTech Innovator. In the following Q&A, Glenn Snyder of Deloitte and Paul Grand of MTI delve into the findings and what they mean for the future of medtech innovation.

#3:At NASS 2021, MIS Spine Pioneer Frank Phillips Talks Augmented Reality, Implants, and Robots

As COVID-19, reimbursement shifts, and AI drive enormous change throughout healthcare, Rush University orthopedics professor Frank Phillips discusses their impacts on some of the most intractable challenges in spine surgery.

#4:Brain-Computer Interfaces: The Internet of Us

Neural interfaces are bringing a new understanding of disease processes, and a way to intervene with devices that speak the language of the brain. The field is burgeoning with good ideas, many still in the realm of research, but there are some focused and relatively near-term medical opportunities.

#5:ObvioHealth Reenvisions Clinical Trials

The current model for clinical trials is in need of reinvention; time is lost and quality is compromised in every step of a process that involves many stakeholders. ObvioHealth is a member of a new class of companies enabling virtual, decentralized clinical trials, which offer potential benefits around recruiting, adherence, retention, and speed to completion.

 

×



Articles from Nancy Dvorin:

Perspective & Commentary

Digital Edition: MedTech Strategist February 2024

We examine the opportunity for intravascular ultrasound in peripheral vascular disease, one of the largest endovascular markets; FIRE1 moves closer to proving the success of its novel approach to heart failure and perhaps the build-to-buy model. Northwell Health's VP of data strategy discusses leveraging the "data lake" to meet clinical and operational needs, both internally and with external partners. Plus profiles of ViCentra, Insight Medbotics, and VUZE Medical.

Read Article